EU antitrust regulators will examine Illumina’s proposed US$7.1 billion acquisition of cancer test maker, the European Commission announced on Tuesday, April 20, following a request from six countries on competition concerns.
US life sciences company Illumina announced last September that it would acquire Grail – which it previously owned before spinning it off as a separate business four years ago – by buying out investors including Amazon founder Jeff Bezos. Illumina had remained the company’s largest shareholder.
While the deal does not reach the turnover threshold that would require Illumina to seek EU approval, France asked the EU competition enforcer to vet the deal under new rules announced last month targeting biotech and tech start-up deals, the Commission stated.
Belgium, Greece, and the Netherlands, as well as non-EU members Norway and Iceland, backed France’s request. Grail makes a non-invasive, early detection biopsy test to screen for many kinds of cancers using DNA sequencing.
“The combined entity could restrict access to or increase prices of next-generation sequencers and reagents to the detriment of Grail’s rivals active in genomic cancer tests following the transaction,” the Commission said in a statement.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI